-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QQ58QHubJ5tDV0y9wMp/7NBo8qN925lWhdN9B3U4P+u1N9VC6XAQkTcHxp3kob7z 2WydfS6YBu7PpAu0WWNPcA== 0000912057-02-037136.txt : 20020927 0000912057-02-037136.hdr.sgml : 20020927 20020927172516 ACCESSION NUMBER: 0000912057-02-037136 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20020927 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF INVESTMENTS, L.L.C. GROUP MEMBERS: BVF PARTNERS L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CORVAS INTERNATIONAL INC CENTRAL INDEX KEY: 0000882100 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330238812 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-42011 FILM NUMBER: 02775308 BUSINESS ADDRESS: STREET 1: 3030 SCIENCE PARK RD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194559800 MAIL ADDRESS: STREET 2: 3030 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 415-288-23 MAIL ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 SC 13D/A 1 a2090152zsc13da.htm SC 13D/A
QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 2)1

    Corvas International, Inc.
(Name of Issuer)		    

 
 
 
 
 
    Common Stock
(Title of Class of Securities)		    

 
 
 
 
 
    221005 10 1
(CUSIP Number)		    

 
 
 
 
 
    Hope Flack
BVF Partners L.P.
227 West Monroe Street, Suite 4800
Chicago, Illinois 60606
(312) 263-7777
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)		    

 
 
 
 
 
    September 25, 2002
(Date of Event Which Requires Filing of this Amendment)		    

        If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ý

        Note:    Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 8 Pages)

1      The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

        The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
CUSIP No. 221005 10 1   13D   Page 2 of 8 Pages
     
1   NAME OF REPORTING PERSON:
 Biotechnology Value Fund, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):		    
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a)  ý
        (b)  o
         
3   SEC USE ONLY    

 
 
 
 
 
4   SOURCE OF FUNDS*    

 
 
WC
 
 
5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)   o

 
 
 
 
 
6   CITIZENSHIP OR PLACE OF ORGANIZATION    

 
 
Delaware
 
 
    7   SOLE VOTING POWER
NUMBER OF       -0-
SHARES  
BENEFICIALLY   8   SHARED VOTING POWER
OWNED       1,867,155
BY  
EACH   9   SOLE DISPOSITIVE POWER
REPORTING       -0-
PERSON  
WITH:   10   SHARED DISPOSITIVE POWER
        1,867,155
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    

 
 
1,867,155
 
 
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*   o

 
 
 
 
 
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    

 
 
6.8%
 
 
14   TYPE OF REPORTING PERSON*    

 
 
PN
 
 

SEE INSTRUCTIONS BEFORE FILLING OUT!

      
CUSIP No. 221005 10 1   13D   Page 3 of 8 Pages
     
1   NAME OF REPORTING PERSON:
 Biotechnology Value Fund II, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):		    
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a)  ý
        (b)  o
         
3   SEC USE ONLY    

 
 
 
 
 
4   SOURCE OF FUNDS*    

 
 
WC
 
 
5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)   o

 
 
 
 
 
6   CITIZENSHIP OR PLACE OF ORGANIZATION    

 
 
Delaware
 
 
    7   SOLE VOTING POWER
NUMBER OF       -0-
SHARES  
BENEFICIALLY   8   SHARED VOTING POWER
OWNED       1,004,711
BY  
EACH   9   SOLE DISPOSITIVE POWER
REPORTING       -0-
PERSON  
WITH:   10   SHARED DISPOSITIVE POWER
        1,004,711
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    

 
 
1,004,711
 
 
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*   o

 
 
 
 
 
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    

 
 
3.6%
 
 
14   TYPE OF REPORTING PERSON*    

 
 
PN
 
 

SEE INSTRUCTIONS BEFORE FILLING OUT!

      
CUSIP No. 221005 10 1   13D   Page 4 of 8 Pages
     
1   NAME OF REPORTING PERSON:
 BVF Investments, L.L.C.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):		    
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a)  ý
        (b)  o
         
3   SEC USE ONLY    

 
 
 
 
 
4   SOURCE OF FUNDS*    

 
 
WC
 
 
5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)   o

 
 
 
 
 
6   CITIZENSHIP OR PLACE OF ORGANIZATION    

 
 
Delaware
 
 
    7   SOLE VOTING POWER
NUMBER OF       -0-
SHARES  
BENEFICIALLY   8   SHARED VOTING POWER
OWNED       2,231,627
BY  
EACH   9   SOLE DISPOSITIVE POWER
REPORTING       -0-
PERSON  
WITH:   10   SHARED DISPOSITIVE POWER
        2,231,627
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    

 
 
2,231,627
 
 
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*   o

 
 
 
 
 
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    

 
 
8.1%
 
 
14   TYPE OF REPORTING PERSON*    

 
 
OO
 
 

SEE INSTRUCTIONS BEFORE FILLING OUT!

      
CUSIP No. 221005 10 1   13D   Page 5 of 8 Pages
     
1   NAME OF REPORTING PERSON:
 BVF Partners L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):		    
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a)  ý
        (b)  o
         
3   SEC USE ONLY    

 
 
 
 
 
4   SOURCE OF FUNDS*    

 
 
OO
 
 
5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)   o

 
 
 
 
 
6   CITIZENSHIP OR PLACE OF ORGANIZATION    

 
 
Delaware
 
 
    7   SOLE VOTING POWER
NUMBER OF       -0-
SHARES  
BENEFICIALLY   8   SHARED VOTING POWER
OWNED       5,341,029
BY  
EACH   9   SOLE DISPOSITIVE POWER
REPORTING       -0-
PERSON  
WITH:   10   SHARED DISPOSITIVE POWER
        5,341,029
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    

 
 
5,341,029
 
 
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*   o

 
 
 
 
 
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    

 
 
19.4%
 
 
14   TYPE OF REPORTING PERSON*    

 
 
PN
 
 

SEE INSTRUCTIONS BEFORE FILLING OUT!

      
CUSIP No. 221005 10 1   13D   Page 6 of 8 Pages
     
1   NAME OF REPORTING PERSON:
 BVF Inc.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):		    
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a)  ý
        (b)  o
         
3   SEC USE ONLY    

 
 
 
 
 
4   SOURCE OF FUNDS*    

 
 
OO
 
 
5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)   o

 
 
 
 
 
6   CITIZENSHIP OR PLACE OF ORGANIZATION    

 
 
Delaware
 
 
    7   SOLE VOTING POWER
NUMBER OF       -0-
SHARES  
BENEFICIALLY   8   SHARED VOTING POWER
OWNED       5,341,029
BY  
EACH   9   SOLE DISPOSITIVE POWER
REPORTING       -0-
PERSON  
WITH:   10   SHARED DISPOSITIVE POWER
        5,341,029
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    

 
 
5,341,029
 
 
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*   o

 
 
 
 
 
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    

 
 
19.4%
 
 
14   TYPE OF REPORTING PERSON*    

 
 
IA, CO
 
 

SEE INSTRUCTIONS BEFORE FILLING OUT!

      
CUSIP No. 221005 10 1   13D   Page 7 of 8 Pages
     

        This Amendment No. 2 to the Statement on Schedule 13D (this "Amendment") is being filed with the Securities and Exchange Commission on behalf of the Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"), Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2"), BVF Investments, L.L.C., a Delaware limited liability company ("Investments"), BVF Partners L.P., a Delaware limited partnership ("Partners") and BVF Inc., a Delaware corporation ("BVF Inc." and, together with BVF, BVF2, Investments, and Partners, the "Reporting Persons") with respect to the Common Stock, par value $0.001 per share (the "Stock"), of Corvas International, Inc., a Delaware corporation ("Corvas"). The principal executive office of Corvas is located at 3030 Science Park Road, San Diego, California 92121.

Item 3 is hereby amended to read in its entirety as follows:


ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

        Since July 29, 2002, Partners, in its capacity as (i) general partner of BVF, has purchased on behalf of such limited partnership an aggregate number of 419,700 shares of the Stock for an aggregate consideration of $538,567.98, utilizing funds provided by BVF from its working capital pursuant to the terms of its limited partnership agreement with Partners; (ii) general partner of BVF2, has purchased on behalf of such limited partnership an aggregate number of 149,000 shares of the Stock for an aggregate consideration of $193,914.36, utilizing funds provided by BVF2 from its working capital pursuant to the terms of its limited partnership agreement with Partners; and (iii) manager of Investments, has purchased on behalf of such limited liability company an aggregate number of 276,400 shares of the Stock for an aggregate consideration of $364,250.16, utilizing funds provided by Investments from its working capital pursuant to the terms of its investment advisory agreement with Partners.

Item 5 is hereby amended to read in its entirety as follows:


ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

        (a)  BVF beneficially owns 1,867,155 shares of the Stock, BVF2 beneficially owns 1,004,711 shares of the Stock, Investments beneficially owns 2,231,627 shares of the Stock and each of Partners and BVF Inc. beneficially owns 5,341,029 shares of the Stock, representing approximately 6.8%, 3.6%, 8.1% and 19.4%, respectively, of the aggregate number of shares of common stock outstanding as of August 8, 2002.

        (b)  Each of BVF, BVF2 and Investments shares with Partners voting and dispositive power over the shares of the Stock each such entity beneficially owns. Partners and BVF Inc. share voting and dispositive power over the 5,341,029 shares of the Stock they beneficially own with, in addition to BVF, BVF2 and Investments, Investment 10, L.L.C., an Illinois limited liability company ("ILL10") and managed account on whose behalf Partners, as investment advisor, purchased such shares. ILL10 specializes in holding biotechnology stocks for investment purposes and its business address is 227 West Monroe Street, Suite 4800, Chicago, Illinois 60606.

        (c)  Exhibit 2 attached hereto contains information as to all transactions in the Stock by the Reporting Persons during the last 60 days. All such transactions were made for cash in open market, over-the-counter transactions. No other transactions in the Stock have been effected by the Reporting Persons during the last 60 days.

        (d)  ILL10 is entitled to receive dividends and any sale proceeds with respect to shares of the Stock in proportion to its respective ownership interest therein.


ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit 1—Agreement Regarding Joint Filing

Exhibit 2—Transactions in the Stock by the Reporting Persons During the Last 60 Days.

     
CUSIP No. 221005 10 1   13D   Page 8 of 8 Pages
     

        After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment is true, complete and correct.

Dated: September 27, 2002    
               
    BIOTECHNOLOGY VALUE FUND, L.P.    
               
    By: BVF Partners L.P., its general partner    
               
      By: BVF Inc., its general partner    
               
        By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               
    BIOTECHNOLOGY VALUE FUND II, L.P.    
               
    By: BVF Partners L.P., its general partner    
               
      By: BVF Inc., its general partner    
               
        By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               
    BVF INVESTMENTS, L.L.C.    
               
    By: BVF Partners L.P., its manager    
               
      By: BVF Inc., its general partner    
               
        By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               
    BVF PARTNERS L.P.    
               
    By: BVF Inc., its general partner    
               
      By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               
    BVF INC.    
               
    By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               


QuickLinks

SCHEDULE 13D
 EX-1 3 a2090152zex-1.htm EXHIBIT 1
QuickLinks -- Click here to rapidly navigate through this document


EXHIBIT 1

AGREEMENT REGARDING JOINT FILING

        The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, BVF Investments, L.L.C., a Delaware limited liability company, BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the information required by Schedule 13D, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.

Dated: September 27, 2002    
               
    BIOTECHNOLOGY VALUE FUND, L.P.    
               
    By: BVF Partners L.P., its general partner    
               
      By: BVF Inc., its general partner    
               
        By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               
    BIOTECHNOLOGY VALUE FUND II, L.P.    
               
    By: BVF Partners L.P., its general partner    
               
      By: BVF Inc., its general partner    
               
        By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               
    BVF INVESTMENTS, L.L.C.    
               
    By: BVF Partners L.P., its manager    
               
      By: BVF Inc., its general partner    
               
        By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               
    BVF PARTNERS L.P.    
               
    By: BVF Inc., its general partner    
               
      By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               
    BVF INC.    
               
    By: /s/  MARK N. LAMPERT      
Mark N. Lampert
President		    
               


QuickLinks

AGREEMENT REGARDING JOINT FILING
 EX-2 4 a2090152zex-2.htm EXHIBIT 2
QuickLinks -- Click here to rapidly navigate through this document


EXHIBIT 2

TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS
DURING THE LAST 60 DAYS

Trade Date
   By
   For the
Account of
   Quantity
   Price per
Share
   Type of Trade
   Broker*
8/29/2002   Partners   BVF   100   $1.3800   Purchase   INET
8/30/2002   Partners   BVF   30,000   $1.3984   Purchase   INET
9/3/2002   Partners   BVF   34,700   $1.2500   Purchase   SMHI
9/9/2002   Partners   BVF   10,900   $1.3283   Purchase   INET
9/12/2002   Partners   BVF   45,000   $1.3300   Purchase   CIBC
9/18/2002   Partners   BVF   1,000   $1.2900   Purchase   INET
9/19/2002   Partners   BVF   1,000   $1.2800   Purchase   INET
9/20/2002   Partners   BVF   11,000   $1.2860   Purchase   INET
9/23/2002   Partners   BVF   20,700   $1.2300   Purchase   INET
9/24/2002   Partners   BVF   91,800   $1.2200   Purchase   INET
9/24/2002   Partners   BVF   1,000   $1.2000   Purchase   GKMC
9/25/2002   Partners   BVF   168,000   $1.2700   Purchase   CIBC
9/25/2002   Partners   BVF   3,800   $1.2300   Purchase   INET
9/26/2002   Partners   BVF   700   $1.2500   Purchase   INET
8/30/2002   Partners   BVF2   15,000   $1.3984   Purchase   INET
9/3/2002   Partners   BVF2   24,000   $1.2500   Purchase   SMHI
9/9/2002   Partners   BVF2   7,000   $1.3283   Purchase   INET
9/12/2002   Partners   BVF2   30,000   $1.3300   Purchase   CIBC
9/18/2002   Partners   BVF2   1,000   $1.2900   Purchase   INET
9/19/2002   Partners   BVF2   1,000   $1.2800   Purchase   INET
9/23/2002   Partners   BVF2   8,000   $1.2300   Purchase   INET
9/25/2002   Partners   BVF2   60,000   $1.2700   Purchase   CIBC
9/25/2002   Partners   BVF2   2,000   $1.2300   Purchase   INET
9/26/2002   Partners   BVF2   1,000   $1.2500   Purchase   INET
8/29/2002   Partners   Investments   1,000   $1.3800   Purchase   INET
8/30/2002   Partners   Investments   50,400   $1.3984   Purchase   INET
9/3/2002   Partners   Investments   54,000   $1.2500   Purchase   SMHI
9/9/2002   Partners   Investments   16,000   $1.3283   Purchase   INET
9/12/2002   Partners   Investments   69,000   $1.3300   Purchase   CIBC
9/18/2002   Partners   Investments   2,000   $1.2900   Purchase   INET
9/19/2002   Partners   Investments   1,000   $1.2800   Purchase   INET
9/23/2002   Partners   Investments   17,000   $1.2300   Purchase   INET
9/25/2002   Partners   Investments   60,000   $1.2700   Purchase   CIBC
9/25/2002   Partners   Investments   5,000   $1.2300   Purchase   INET
9/26/2002   Partners   Investments   1,000   $1.2500   Purchase   INET
9/3/2002   Partners   ILL10   5,000   $1.2500   Purchase   SMHI
9/9/2002   Partners   ILL10   1,000   $1.3283   Purchase   INET
9/12/2002   Partners   ILL10   6,000   $1.3300   Purchase   CIBC
9/23/2002   Partners   ILL10   2,000   $1.2300   Purchase   INET
9/25/2002   Partners   ILL10   12,000   $1.2700   Purchase   CIBC

*Broker Codes

CIBC
—
 
CIBC Oppenheimer
INET —   Instinet
GKMC —   Gerald Klauer Mattison & Co.
SMHI —   Sanders Morris Harris


QuickLinks

TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS DURING THE LAST 60 DAYS
 -----END PRIVACY-ENHANCED MESSAGE-----